



INSIDE THIS ISSUE

- Communities Oncology Network Pharmacy Survey
- Benefit Drug List
- Protocol Update – LUDOC, ULUPG, LUPE
- Cancer Management Manual
- Pre-Printed Order Update – BRAJCEF, UBRAVTR, BRAVTRNAV, ENAVD, GIFUINF, GIIRFUFA, GUMVAC, GUPM, KSVB, LYABVD, PUM, SCPAINSU
- Patient Education Update - Thalidomide
- Drug Update – Guidelines for Maximum Lifetime Doses of Anthracyclines in Adults
- Provincial Systemic Therapy Program Policies
- Communities Oncology Network - Survey
- Library/Cancer Information Centre

FAX request form and IN TOUCH phone list are provided if additional information is needed.

COMMUNITIES ONCOLOGY NETWORK PHARMACY SURVEY

Needs Assessment for CON Pharmacists

BC Cancer Agency communication with its community partners indicated pharmacy oncology education as an important priority. At the Partners in Cancer Care Conference held in November 2001, a needs-assessment was identified as an appropriate tool to assess the developmental goals of oncology pharmacists and technicians. In the coming month, the CON pharmacy sites will be receiving the Pharmacy CON Survey for completion. This survey will enable the Pharmacy CON Educators to determine what the CON pharmacists view as their top priorities for a pharmacy oncology education program. Information received from the survey will be directly applied to the creation of the first pilot module of the pharmacy oncology education program. Your time and effort in completing the survey will be greatly appreciated.

If you have any questions or concerns, please contact your regional Pharmacy CON Educator:

Fraser Valley: Dawn Annable (604) 930-4002
Southern Interior: Kimberly Kuik (250) 712-3953
Vancouver: Shawn Cassidy (604) 877-6135
Vancouver Island: Nancy Coady (250) 519-5510

BENEFIT DRUG LIST

The current Benefit Drug List and Class II forms are available on the website www.bccancer.bc.ca.

PROTOCOL UPDATE

Protocols by Drugs Index A cross-referenced index lists the BC Cancer Agency benefit drugs with their corresponding protocols. This index can be obtained via H-drive at regional cancer centres or Fax-back as listed at the end of the Update. Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

- **INDEX to BC Cancer Agency Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **LUDOC** revised (liver function tests, reference): Second-line treatment for advanced non-small cell lung cancer with docetaxel
- **ULUPG** new: Treatment of malignant mesothelioma with cisplatin and gemcitabine (undesigned protocol)
- **LUPE** revised (carboplatin added as alternative to cisplatin): Palliative therapy of selected solid tumours using cisplatin and etoposide (interim version)

Protocols are available on the BC Cancer Agency website www.bccancer.bc.ca/ccp/.

CANCER MANAGEMENT MANUAL

The Cancer Management Manual is available on BCCA website www.bccancer.bc.ca/cmm/.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol

summaries. The BC Cancer Agency Vancouver Centre has prepared chemotherapy pre-printed orders, which can be used as a guide for reference. An index to the orders can be obtained by Fax-back.

BRAJCEF revised (appointments): Adjuvant therapy for breast cancer using cyclophosphamide, epirubicin and fluorouracil

UBRAVTR revised (indications clarified): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) via Special Access Program

BRAVTRNAV revised (indications clarified): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and vinorelbine

ENAVD new: Palliative therapy for advanced endocrine cancers using doxorubicin

GIFUINF revised (appointments): Palliative therapy for metastatic colorectal adenocarcinoma using Fluorouracil infusional chemotherapy

GIIRFUFA revised (appointments and chemotherapy section): First-line palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)

GUMVAC revised (vinblastine push): Therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin

GUPM new: Therapy for hormone-resistant metastatic carcinoma of the prostate using mitomycin monotherapy

KSVB revised (vinblastine push): Therapy for Kaposi's sarcoma with Vinblastine-Vincristine

LYABVD revised (vinblastine push, dacarbazine alternative): Treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine

PUM revised (appointments): Monotherapy for metastatic carcinomas of unknown primary using mitomycin

SCPAINSU revised (reference to protocol added below the title): Incident pain therapy using sufentanil via sublingual route

PATIENT EDUCATION UPDATE

Thalidomide Patient Handout has been revised to clarify the administration instructions. Previously, patients were advised to take the medication at least one hour after meals. This has now been changed to "preferably", rather than an absolute requirement.

DRUG UPDATE

Guidelines for Maximum Lifetime Doses of Anthracyclines in Adults Cardiac toxicity is a well-documented side effect of anthracyclines. Risk increases with cumulative dose, especially in patients with known risk factors such as thoracic radiation therapy and exposure to other potentially cardiotoxic agents. One must consider the total cumulative dose the patient has received in his/her lifetime, as there is a maximum cumulative dose at which time a cardiac assessment and/or consultation with an oncologist should be considered before continuing treatment.

Kimberly Kuik
Pharmacy CON Educator
BC Cancer Agency-Southern Interior Centre

CANCER DRUG MANUAL

The Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES

The BC Cancer Agency Systemic Therapy Policies are available at h:\everyone\systemic\prov\chemo\policies on the H-drive at the regional cancer centres and on www.bccancer.bc.ca/ccp/appendices.shtml in the BC Cancer Agency website.

COMMUNITIES ONCOLOGY NETWORK

Communities Oncology Network Pharmacy Survey An education needs assessment will be sent out to the CON pharmacists in the coming month. See the lead article for more details.

LIBRARY/CANCER INFORMATION CENTRE

Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/uct/. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the manual provides proponent/advocate claims, as well as evidence-based evaluation/critique quotations from the literature.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD

Sandra Broughton, BA (Econ), MSc

Karen Janes, MSN

David Noble, BSc, BLS

Jaya Venkatesh, BCom, BA, MHA

Susan Walisser, BSc (Pharm)

Gigi Concon (Secretary)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	jvenkate@bccancer.bc.ca
Education Resource Nurse	Ext 2638	nursinged@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	francish@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Centre (FVCC)	(604)-930-2098	Toll-Free 1-(800)-523-2885
Vancouver Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Centre (VICC)	(250) 519-5500	Toll-Free 1-(800)-670-3322

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Patient Education Handouts	H:\everyone\systemic\chemo\pt_educ\drugs\ Thalidomide handout
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
Index of Pre-Printed Orders	Index.doc
	BRAJCEF GUMVAC
	UBRAVTR GUPM
	BRAVTRNAV KSVB
	ENAVD LYABVD
	GIFUINF PUM
	GIIRFUFA SCPAINSU
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\tumour site"
Index of Protocol Summaries	Index_NT or Index_W6
	LUDOC LUPE
	ULUPG
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List (1 March 2002)	BenefitList.doc
Class 2 Form (1 February 2002)	Class2.doc
Filgrastim Usage Form (1 June 2001)	GCSF_form.doc
Undesignated Indication Form (November 2001)	Undesig.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca

BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

E-mail (Word 6.0)

@

Fax

()

Attn:

UPDATES Please Fax-Back information below:

Add breast protocols

<input type="checkbox"/> All items	
Patient Education Handouts:	
<input type="checkbox"/> Thalidomide	
Pre-Printed Orders:	
<input type="checkbox"/> Index: Pre-Printed Orders	
<input type="checkbox"/> BRAJCEF	<input type="checkbox"/> GUMVAC
<input type="checkbox"/> UBRAVTR	<input type="checkbox"/> GUPM
<input type="checkbox"/> BRAVTRNAV	<input type="checkbox"/> KSVB
<input type="checkbox"/> ENAVD	<input type="checkbox"/> LYABVD
<input type="checkbox"/> GIFUINF	<input type="checkbox"/> PUM
<input type="checkbox"/> GIIRFUFA	<input type="checkbox"/> SCPAINSU
Protocol Summaries: (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> Index: Protocol Summaries (current month)	
<input type="checkbox"/> LUDOC	<input type="checkbox"/> LUPE
<input type="checkbox"/> ULUPG	
Reimbursement (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> Benefit Drug List (01 March 2002)	
<input type="checkbox"/> Class 2 Form (01 February 2001)	
<input type="checkbox"/> Filgrastim Usage Form (01 June 2001)	
<input type="checkbox"/> Undesignated Indication Form (November 2001)	
Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)	
<input type="checkbox"/> Jan-Dec 2000	
<input type="checkbox"/> Jan-Dec 2001	